CP-101(Finch Therapeutics Group)

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameCP-101(Finch Therapeutics Group)
Drug Alias NameFull-Spectrum Microbiota
ClassificationBiologics > Live BiotherapeuticNatural product/Extract > Microbial extract
Mechanisms of ActionGastrointestinal microbiome modulatorsBacteria replacements
TargetsNot applicable
Therapy Area/IndicationsUrethritisRenal Insufficiency, ChronicColitis, Ulcerative +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesFinch Research and Development LLC
China Registration ClassN/A

Develop Information

Active CompaniesThe Brigham and Women's Hospital
Inactive CompaniesFinch Research and Development LLC
Active IndicationsColitis, Ulcerative
Inactive IndicationsUrethritisRenal Insufficiency, ChronicClostridium Infections

Other Information

ATC CodeN/A
Related LinksN/A